RecallRadar

FDA Drug recall D-1000-2020

Quetiapine Fumarate Extended-Release Tablets, 150 mg, 100 tablets per unit dose carton, Rx only, Manufactured by: Lupin Limited, Pithampur…

On 2020-03-18 the FDA classified a Class III recall of Quetiapine Fumarate Extended-Release Tablets, 150 mg, 100 tablets per unit dose carton, Rx only, Manufactured by: Lupin Limited, Pithampur… by The Harvard Drug Group, citing labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-1000-2020
ClassificationClass III
Statusterminated
Initiated2020-02-27
Published2020-03-18
Last updated2026-09-13 11:52 UTC
CompanyThe Harvard Drug Group
DistributionUS

Product

Quetiapine Fumarate Extended-Release Tablets, 150 mg, 100 tablets per unit dose carton, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.) 454775 India; Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152 USA. NDC: 0904-6802-61

Reason

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Identifiers

ndc0904-6801-61
ndc0904-6802-61
ndc0904-6803-61
ndc0904-6804-61
ndc0904-6805-61
code_infoLot, expiry: Lot N00036, exp 05/2021

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1000-2020%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.